UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Understanding, recognizing, and managing toxicities of targeted anticancer therapies

CA: a cancer journal for clinicians, 2013-07, Vol.63 (4), p.249-279

2013

Volltextzugriff (PDF)

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

The New England journal of medicine, 2021-06, Vol.384 (25), p.2371-2381

2021

Volltextzugriff (PDF)

Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100

Journal of clinical oncology, 2023-06, Vol.41 (18), p.3311-3317

2023

Volltextzugriff (PDF)

T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors

Nature communications, 2021-03, Vol.12 (1), p.1402-1402, Article 1402

2021

Volltextzugriff (PDF)

Advances in Cancer Immunotherapy in Solid Tumors

Cancers, 2016-11, Vol.8 (12), p.106

2016

Volltextzugriff (PDF)

First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel

International journal of nanomedicine, 2014-01, Vol.9 (Issue 1), p.209-221

2014

Volltextzugriff (PDF)

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.1560-1568

2018

Volltextzugriff (PDF)

Ocular adverse events associated with antibody-drug conjugates for cancer: evidence and management strategies

The oncologist (Dayton, Ohio), 2024-07, Vol.29 (11), p.e1435

2024

Volltextzugriff (PDF)

Simultaneous Detection of Tumor Derived Exosomal Protein–MicroRNA Pairs with an Exo-PROS Biosensor for Cancer Diagnosis

ACS nano, 2023-05, Vol.17 (9), p.8108-8122

2023

Volltextzugriff (PDF)

Small Cell Lung Cancer

Mayo Clinic proceedings, 2008-03, Vol.83 (3), p.355-367

2008

Volltextzugriff (PDF)

CodeBreak 200: study limitations, and future directions

Translational cancer research, 2024-01, Vol.13 (1), p.15-21

2024

Volltextzugriff (PDF)

A CURE on the Evolution of Antibiotic Resistance in "Escherichia coli" Improves Student Conceptual Understanding

CBE - Life Sciences Education, 2023-03, Vol.22 (1), p.ar7-ar7

2023

Volltextzugriff (PDF)

JASPER: Phase 2 trial of first‐line niraparib plus pembrolizumab in patients with advanced non–small cell lung cancer

Cancer, 2022-01, Vol.128 (1), p.65-74

2022

Volltextzugriff (PDF)

Sensitive Detection of Exosomal Proteins via a Compact Surface Plasmon Resonance Biosensor for Cancer Diagnosis

ACS sensors, 2018-08, Vol.3 (8), p.1471-1479

2018

Volltextzugriff (PDF)

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature

Case reports in oncology, 2019-01, Vol.12 (1), p.260-276

2019

Volltextzugriff (PDF)

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients With Unresectable NSCLC Undergoing Chemoradiation Therapy

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.e19-e20

2021

Volltextzugriff (PDF)

Trilaciclib use in extensive-stage small cell lung cancer (ES-SCLC): are clinical benefits seen in the real-world setting?

Supportive care in cancer, 2024-09, Vol.32 (9), p.622, Article 622

2024

Volltextzugriff (PDF)

Prolonged Disease Control Despite ALK Inhibitor Discontinuation in Advanced ALK-Positive NSCLC

European journal of case reports in internal medicine, 2024-04, Vol.11 (6), p.004527

2024

Volltextzugriff (PDF)

Targeted therapies in development for non-small cell lung cancer

Journal of carcinogenesis, 2013-01, Vol.12 (1), p.22-22

2013

Volltextzugriff (PDF)

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study

Journal of thoracic oncology, 2015-09, Vol.10 (9), p.1319-1327

2015

Volltextzugriff (PDF)

Patients' Preferences for Adjuvant Osimertinib in Non–Small-Cell Lung Cancer After Complete Surgical Resection: What Makes It Worth It to Patients?

Clinical lung cancer, 2024-09, Vol.25 (6), p.509-518

2024

Volltextzugriff (PDF)

Survival outcomes of alternate dosing schedule of pemetrexed as maintenance therapy in NSCLC: Single institution experience

Lung cancer (Amsterdam, Netherlands), 2022-03, Vol.165, p.49-53

2022

Volltextzugriff (PDF)

The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer

Frontiers in oncology, 2021-06, Vol.11, p.639745

2021

Volltextzugriff (PDF)

Undergraduate Textbook Representations of Meiosis Neglect Essential Elements

The American biology teacher, 2020-05, Vol.82 (5), p.296-305

2020

Volltextzugriff (PDF)

Body Mass Index Influences the Salutary Effects of Metformin on Survival After Lobectomy for Stage I NSCLC

Journal of thoracic oncology, 2019-12, Vol.14 (12), p.2181-2187

2019

Volltextzugriff (PDF)

1 – 25 von 286

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(263)
Mit Volltextzugriff
(265)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(140)
Life Sciences & Biomedicine
(134)
Humans
(107)
Oncology
(98)
Female
(71)
Male
(65)
Aged
(61)
Middle Aged
(61)
Lung Neoplasms - Drug Therapy
(42)
Adult
(41)
Tumors
(37)
Biological And Medical Sciences
(34)
Lung Cancer
(34)
Medical Sciences
(34)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(32)
Aged, 80 And Over
(30)
Respiratory System
(27)
Lung Neoplasms - Pathology
(25)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(24)
Patients
(24)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Understanding, recognizing, and managing toxicities of targeted anticancer therapies

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100

T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors

Advances in Cancer Immunotherapy in Solid Tumors

First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC

Ocular adverse events associated with antibody-drug conjugates for cancer: evidence and management strategies

Simultaneous Detection of Tumor Derived Exosomal Protein–MicroRNA Pairs with an Exo-PROS Biosensor for Cancer Diagnosis

Small Cell Lung Cancer

CodeBreak 200: study limitations, and future directions

A CURE on the Evolution of Antibiotic Resistance in "Escherichia coli" Improves Student Conceptual Understanding

JASPER: Phase 2 trial of first‐line niraparib plus pembrolizumab in patients with advanced non–small cell lung cancer

Sensitive Detection of Exosomal Proteins via a Compact Surface Plasmon Resonance Biosensor for Cancer Diagnosis

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients With Unresectable NSCLC Undergoing Chemoradiation Therapy

Trilaciclib use in extensive-stage small cell lung cancer (ES-SCLC): are clinical benefits seen in the real-world setting?

Prolonged Disease Control Despite ALK Inhibitor Discontinuation in Advanced ALK-Positive NSCLC

Targeted therapies in development for non-small cell lung cancer

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study

Patients' Preferences for Adjuvant Osimertinib in Non–Small-Cell Lung Cancer After Complete Surgical Resection: What Makes It Worth It to Patients?

Survival outcomes of alternate dosing schedule of pemetrexed as maintenance therapy in NSCLC: Single institution experience

The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer

Undergraduate Textbook Representations of Meiosis Neglect Essential Elements

Body Mass Index Influences the Salutary Effects of Metformin on Survival After Lobectomy for Stage I NSCLC

Suchergebnisse filtern